[go: up one dir, main page]

MX2009000506A - Composiciones y metodos para el tratamiento de la mucormicosis y otras enfermedades micoticas. - Google Patents

Composiciones y metodos para el tratamiento de la mucormicosis y otras enfermedades micoticas.

Info

Publication number
MX2009000506A
MX2009000506A MX2009000506A MX2009000506A MX2009000506A MX 2009000506 A MX2009000506 A MX 2009000506A MX 2009000506 A MX2009000506 A MX 2009000506A MX 2009000506 A MX2009000506 A MX 2009000506A MX 2009000506 A MX2009000506 A MX 2009000506A
Authority
MX
Mexico
Prior art keywords
antifungal agent
iron chelating
fungal condition
chelating compound
composition
Prior art date
Application number
MX2009000506A
Other languages
English (en)
Inventor
Ashraf S Ibrahim
Brad J Spellberg
John E Edwards
Original Assignee
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Los Angeles Biomed Res Inst filed Critical Los Angeles Biomed Res Inst
Publication of MX2009000506A publication Critical patent/MX2009000506A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención proporciona una composición que incluye al menos un compuesto quelante del hierro y al menos un agente antimicótico; la composición puede incluir los compuestos quelantes del hierro deferiprona o deferasirox; un agente antimicótico incluido en la composición puede incluir un agente antimicótico de polieno, un agente antimicótico de azol o un agente antimicótico de equinocandina; la invención también proporciona un método para tratar o prevenir una condición micótica; el método incluye administrar a un individuo que tiene, o es susceptible de tener una condición micótica, una cantidad terapéuticamente efectiva de al menos un compuesto quelante del hierro, durante un tiempo suficiente para reducir la severidad de una condición micótica, en donde el compuesto quelante del hierro comprende un no sideróforo o un no xenosideróforo, con relación a la condición micótica; un método para tratar o prevenir una condición micótica, proporcionado por la invención, también puede incluir administrar a un individuo que tiene, o que es susceptible de tener una condición micótica, una cantidad terapéuticamente efectiva de al menos un compuesto quelante del hierro y al menos un agente antimicótico; se proporciona además por la invención, un método que incluye la administración profiláctica de al menos un compuesto quelante del hierro o al menos un compuesto quelante del hierro y al menos un agente antimicótico, antes del inicio de la condición micótica.
MX2009000506A 2006-07-13 2007-07-13 Composiciones y metodos para el tratamiento de la mucormicosis y otras enfermedades micoticas. MX2009000506A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83109906P 2006-07-13 2006-07-13
US89762007P 2007-01-26 2007-01-26
US90407507P 2007-02-27 2007-02-27
PCT/US2007/016065 WO2008008537A2 (en) 2006-07-13 2007-07-13 Combi) compositions for the treatment of mucormycosis. comprising iron chelator and antifungal agent

Publications (1)

Publication Number Publication Date
MX2009000506A true MX2009000506A (es) 2009-05-20

Family

ID=38610625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009000506A MX2009000506A (es) 2006-07-13 2007-07-13 Composiciones y metodos para el tratamiento de la mucormicosis y otras enfermedades micoticas.

Country Status (18)

Country Link
US (1) US20100129434A1 (es)
EP (2) EP2412371A1 (es)
JP (2) JP2009543788A (es)
KR (1) KR20090036587A (es)
AU (1) AU2007272781B2 (es)
BR (1) BRPI0714221A2 (es)
CA (1) CA2657634A1 (es)
CL (1) CL2007002026A1 (es)
IL (1) IL196389A0 (es)
MA (1) MA30625B1 (es)
MX (1) MX2009000506A (es)
NO (1) NO20090565L (es)
NZ (1) NZ574862A (es)
RU (1) RU2464024C2 (es)
SG (1) SG177122A1 (es)
TN (1) TN2009000004A1 (es)
TW (1) TWI448285B (es)
WO (1) WO2008008537A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ614255A (en) * 2009-03-19 2015-03-27 Los Angeles Biomed Res Inst Vaccine compositions and methods for treatment of mucormycosis and other fungal diseases
US8980876B2 (en) 2010-10-28 2015-03-17 The Procter & Gamble Company Inhibition of microbial growth by aconitase inhibition
KR20150084771A (ko) * 2012-11-12 2015-07-22 시플라 리미티드 데페라시록스 및 데페리프론를 포함하는 고정 투여량 약학 조성물
WO2014120774A1 (en) 2013-01-29 2014-08-07 Case Western Reserve University Fungal iron acquisition inhibitors and uses thereof
US20160199361A1 (en) * 2013-08-19 2016-07-14 Rutgers, The State University Of New Jersey Method of Inducing An Anti-Retroviral Immune Response By Counter-Acting Retro-Virus Induced Anti-Apoptosis
US20170231910A1 (en) * 2014-08-13 2017-08-17 Mark E. Hayes Pharmaceutical formulations of chelating agents as a metal removal treatment system
WO2016025559A1 (en) * 2014-08-13 2016-02-18 Zoneone Pharma, Inc. Pharmaceutical formulations of and methods to prepare chelating agents for efficient metal removal treatment systems
WO2017035582A1 (en) * 2015-08-31 2017-03-09 The University Of Adelaide Methods and products for preventing and/or treating microorganism infections comprising iron chelators and non-iron porphyrins
EP3454944B1 (en) 2016-05-13 2022-07-13 The Brigham and Women's Hospital, Inc. Volatile metabolite profiles for the diagnosis and treatment of mucorales fungi
FR3095755A1 (fr) * 2019-05-10 2020-11-13 Balmes Transplantation Nouveaux médicaments cytoprotecteurs
WO2020264076A1 (en) 2019-06-28 2020-12-30 The Procter & Gamble Company Light augmented treatment method
JP2023057423A (ja) * 2021-10-11 2023-04-21 国立大学法人 熊本大学 ムコール症治療薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8329043D0 (en) * 1983-10-31 1983-11-30 Hider R C Pharmaceutical compositions
US4698431A (en) * 1985-11-12 1987-10-06 The United States Of America As Represented By The United States Department Of Energy Hydroxypyridonate chelating agents
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
TW533205B (en) 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
WO1999009997A1 (en) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Edta and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
EP1223308B1 (de) 2000-12-16 2007-01-24 ALSTOM Technology Ltd Komponente einer Strömungsmaschine
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
ITMI20022447A1 (it) * 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
KR20050088242A (ko) * 2002-12-31 2005-09-02 넥타르 테라퓨틱스 진균 감염 요법을 위한 에어로졸화가능한 약제학적 제형물
WO2004108114A2 (en) * 2003-03-31 2004-12-16 Dinesh Shantilal Patel Anti-fungal composition and a process for its manufacture
DE10356409B4 (de) * 2003-11-28 2006-12-28 Biofrontera Discovery Gmbh Neues Arzneimittel Oxachelin und Derivate

Also Published As

Publication number Publication date
SG177122A1 (en) 2012-01-30
CL2007002026A1 (es) 2008-06-06
BRPI0714221A2 (pt) 2013-01-01
EP2043636A2 (en) 2009-04-08
JP2013040212A (ja) 2013-02-28
TWI448285B (zh) 2014-08-11
WO2008008537A3 (en) 2008-04-24
WO2008008537A2 (en) 2008-01-17
AU2007272781B2 (en) 2012-10-18
US20100129434A1 (en) 2010-05-27
TW200816994A (en) 2008-04-16
JP2009543788A (ja) 2009-12-10
CA2657634A1 (en) 2008-01-17
KR20090036587A (ko) 2009-04-14
RU2009104961A (ru) 2010-08-20
AU2007272781A1 (en) 2008-01-17
NZ574862A (en) 2012-02-24
MA30625B1 (fr) 2009-08-03
RU2464024C2 (ru) 2012-10-20
TN2009000004A1 (en) 2010-08-19
NO20090565L (no) 2009-03-30
IL196389A0 (en) 2009-09-22
EP2412371A1 (en) 2012-02-01

Similar Documents

Publication Publication Date Title
MX2009000506A (es) Composiciones y metodos para el tratamiento de la mucormicosis y otras enfermedades micoticas.
WO2004078138A3 (en) Prophylactic treatment of uv-induced epidermal neoplasia
TNSN07121A1 (en) Synergistic fungicidal compositions
WO2007112000A3 (en) Treatment of pain
MX2010008102A (es) Compuestos fungicidas heterociclicos.
CO6511232A2 (es) Combinaciones fungicidas sinérgicas que contienen una ditiino-tetracarboximida fungicida
MY148424A (en) Fungicidal azocyclic amides
MX2010001565A (es) Compuestos triazolicos que modulan la actividad de proteina de choque termico (hsp) 90.
WO2007106192A3 (en) Inhibitors of iap
UA103614C2 (uk) Лікарський засіб, що містить комбінацію інгібітора кінази та анти-гліпікан 3-антитіла, для лікування раку печінки
WO2011047439A8 (en) Novel parasite therapy
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX2010007584A (es) Inhibidores de proteina cinasa y uso de los mismos.
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
MX2009005551A (es) Uso de inhibidores de iap para el tratamiento de leucemia mieloide aguda.
WO2002036129A3 (de) Topische behandlung von mastalgie mit aromatase-hemmern, wie androstendion
TNSN08447A1 (en) Combination comprising an iron chelator and an anti-neoplastic agent and use thereof
NZ759647A (en) Agent for preventing or treating spinocerebellar ataxia
WO2007015841A3 (en) A method for treating preeclampsia
WO2007030360A3 (en) P13k inhibitors for the treatment of endometriosis
WO2002055022A3 (en) Active metabolite of antifungal compound
TW200742580A (en) Methods for treating nephrolithiasis
WO2006101909A3 (en) Combination therapy for treating or preventing diseases
TNSN08479A1 (en) Method of treatment of hereditary hemochromatosis
WO2008016665A3 (en) Imidazoacridine compounds for treating flt3 -mediated disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal